ImageneBio Inc
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is IMA moving today?
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
IMA overview
Related filings and maps
Congress activity in IMA
No receipt-qualified Congressional disclosure is present for IMA in the cached public ledger.
IMA contract awards, year to date.
Public federal awards linked to this ticker.
IMA lobbying filings, year to date.
Registered lobbying filings matched to ImageneBio Inc.